Table 2.

Univariate and Multivariate analysis of C12orf59 expression and various clinicopathological parameters in training and validation cohort patients with GC

Variables	Training cohort				Validation cohort
	Case	HR	95% CI	P-value	Case	HR	95% CI	P-value
Univariate analysis
Age
≤ 60a	100	1.0			78	1.0
>60	70	1.751	1.059–2.895	0.029	54	1.195	0.620–2.301	0.595
Gender
Female	109	1.0			88	1.0
Male	61	0.992	0.588–1.672	0.975	44	1.316	0.673–2.574	0.422
WHO grade
G1/2	56	1.0			38	1.0
G3	114	1.265	0.723–2.214	0.411	94	1.911	0.836–4.364	0.125
Tumor size(cm)
≤ 5b	91	1.0			97	1.0
>5	79	1.758	1.060–2.916	0.029*	35	2.165	1.116–4.203	0.022
T status
T1/2	37	1.0			44	1.0
T3/4	133	7.234	2.264–23.119	0.001*	88	2.304	1.008–5.264	0.048*
N status
N0	58	1			61	1
N1	112	3.722	1.833–7.558	< 0.001	71	3.823	1.738–8.409	0.001*
Clinical stage
I + II	69	1			70	1
III	101	4.677	2.371–9.227	< 0.001	62	4.308	2.022–9.180	< 0.001*
C12orf59 expression
Low expression	102	1.0			79	1.0
High expression	68	13.497	6.790–26.832	< 0.001*	53	3.326	1.680–6.582	0.001*
Multivariate analysis
Age
≤ 60a	100	1.0			78	1.0
>60	70	0.98	0.580–1.657	0.941	54	1.021	0.520–2.007	0.952
T status
T1/2	37	1.0			44	1.0
T3/4	133	6.351	1.944–20.752	0.002	88	1.35	0.568–3.210	0.497
N status
N0	58	1.0			61	1.0
N1	112	1.690	0.818–3.489	0.156	71	2.875	1.269–6.512	0.011*
Tumor size(cm)
≤ 5b	91	1.0			97	1.0
>5	79	1.405	0.832–2.374	0.203	35	1.404	0.701–2.810	0.338
C12orf59 expression
Low expression	102	1.0			79	1.0
High expression	68	13.012	6.402–26.446	< 0.001*	53	2.656	1.311–5.380	0.007*

a Mean age. b Mean tumor size. Cox propotional hazard regression model, enter; HR Hazard ratio, CI Confidence interval;*Statistically significant difference